WANG, S.S., M. CARRINGTON, S.I. BERNDT, S.L. SLAGER, P.M. BRACCI, J. VOUTSINAS, J.R. CERHAN, K.E. SMEDBY, H. HJALGRIM, J. VIJAI, L.M. MORTON, R. VERMEULEN, O. PALTIEL, C.M. VAJDIC, M.S. LINET, A. NIETERS, S. de SANJOSE, W. COZEN, E.E. BROWN, J. TURNER, J.J. SPINELLI, T.Z. ZHENG, B.M. BIRMANN, C.R. FLOWERS, N. BECKER, E.A. HOLLY, E. KANE, D. WEISENBURGER, M. MAYNADIE, P. COCCO, D. ALBANES, S.J. WEINSTEIN, L.R. TERAS, W.R. DIVER, S.J. LAX, R.C. TRAVIS, R. KAAKS, E. RIBOLI, Y. BENAVENTE, P. BRENNAN, J. MCKAY, M.H. DELFAU-LARUE, B.K. LINK, C. MAGNANI, M.G. ENNAS, G. LATTE, A.L. FELDMAN, N.W. DOO, G.G. GILES, M.C. SOUTHEY, R.L. MILNE, K. OFFIT, J. MUSINSKY, A.A. ARSLAN, M.P. PURDUE, H.O. ADAMI, M. MELBYE, B. GLIMELIUS, L. CONDE, N.J. CAMP, M. GLENN, K. CURTIN, J. CLAVEL, A. MONNEREAU, D.G. COX, H. GHESQUIERES, G. SALLES, P. BOFETTA, Lenka FORETOVÁ, A. STAINES, S. DAVIS, R.K. SEVERSON, Q. LAN, A. BROOKS-WILSON, M.T. SMITH, E. ROMAN, A. KRICKER, Y.W. ZHANG, P. KRAFT, S.J. CHANOCK, N. ROTHMAN, P. HARTGE and C.F. SKIBOLA. HLA Class I and II Diversity Contributes to the Etiologic Heterogeneity of Non-Hodgkin Lymphoma Subtypes. Cancer Research. PHILADELPHIA: AMER ASSOC CANCER RESEARCH, 2018, vol. 78, No 14, p. 4086-4096. ISSN 0008-5472. Available from: https://dx.doi.org/10.1158/0008-5472.CAN-17-2900.
Other formats:   BibTeX LaTeX RIS
Basic information
Original name HLA Class I and II Diversity Contributes to the Etiologic Heterogeneity of Non-Hodgkin Lymphoma Subtypes
Authors WANG, S.S. (840 United States of America), M. CARRINGTON (840 United States of America), S.I. BERNDT (840 United States of America), S.L. SLAGER (840 United States of America), P.M. BRACCI (840 United States of America), J. VOUTSINAS (840 United States of America), J.R. CERHAN (840 United States of America), K.E. SMEDBY (840 United States of America), H. HJALGRIM (208 Denmark), J. VIJAI (840 United States of America), L.M. MORTON (840 United States of America), R. VERMEULEN (528 Netherlands), O. PALTIEL (376 Israel), C.M. VAJDIC (36 Australia), M.S. LINET (840 United States of America), A. NIETERS (276 Germany), S. de SANJOSE (724 Spain), W. COZEN (840 United States of America), E.E. BROWN (840 United States of America), J. TURNER (36 Australia), J.J. SPINELLI (124 Canada), T.Z. ZHENG (840 United States of America), B.M. BIRMANN (840 United States of America), C.R. FLOWERS (840 United States of America), N. BECKER (276 Germany), E.A. HOLLY (840 United States of America), E. KANE (826 United Kingdom of Great Britain and Northern Ireland), D. WEISENBURGER (840 United States of America), M. MAYNADIE (250 France), P. COCCO (380 Italy), D. ALBANES (840 United States of America), S.J. WEINSTEIN (840 United States of America), L.R. TERAS (840 United States of America), W.R. DIVER (840 United States of America), S.J. LAX (826 United Kingdom of Great Britain and Northern Ireland), R.C. TRAVIS (826 United Kingdom of Great Britain and Northern Ireland), R. KAAKS (276 Germany), E. RIBOLI (826 United Kingdom of Great Britain and Northern Ireland), Y. BENAVENTE (826 United Kingdom of Great Britain and Northern Ireland), P. BRENNAN (724 Spain), J. MCKAY (250 France), M.H. DELFAU-LARUE (250 France), B.K. LINK (840 United States of America), C. MAGNANI (380 Italy), M.G. ENNAS (380 Italy), G. LATTE (380 Italy), A.L. FELDMAN (840 United States of America), N.W. DOO (36 Australia), G.G. GILES (36 Australia), M.C. SOUTHEY (36 Australia), R.L. MILNE (36 Australia), K. OFFIT (208 Denmark), J. MUSINSKY (208 Denmark), A.A. ARSLAN (840 United States of America), M.P. PURDUE (840 United States of America), H.O. ADAMI (752 Sweden), M. MELBYE (840 United States of America), B. GLIMELIUS (752 Sweden), L. CONDE (826 United Kingdom of Great Britain and Northern Ireland), N.J. CAMP (840 United States of America), M. GLENN (840 United States of America), K. CURTIN (840 United States of America), J. CLAVEL (250 France), A. MONNEREAU (250 France), D.G. COX (826 United Kingdom of Great Britain and Northern Ireland), H. GHESQUIERES (250 France), G. SALLES (250 France), P. BOFETTA (840 United States of America), Lenka FORETOVÁ (203 Czech Republic, belonging to the institution), A. STAINES (826 United Kingdom of Great Britain and Northern Ireland), S. DAVIS (840 United States of America), R.K. SEVERSON (840 United States of America), Q. LAN (840 United States of America), A. BROOKS-WILSON (124 Canada), M.T. SMITH (840 United States of America), E. ROMAN (826 United Kingdom of Great Britain and Northern Ireland), A. KRICKER (36 Australia), Y.W. ZHANG (840 United States of America), P. KRAFT (840 United States of America), S.J. CHANOCK (840 United States of America), N. ROTHMAN (840 United States of America), P. HARTGE (840 United States of America) and C.F. SKIBOLA (840 United States of America).
Edition Cancer Research, PHILADELPHIA, AMER ASSOC CANCER RESEARCH, 2018, 0008-5472.
Other information
Original language English
Type of outcome Article in a journal
Field of Study 30204 Oncology
Country of publisher United States of America
Confidentiality degree is not subject to a state or trade secret
WWW URL
Impact factor Impact factor: 8.378
RIV identification code RIV/00216224:14110/18:00106857
Organization unit Faculty of Medicine
Doi http://dx.doi.org/10.1158/0008-5472.CAN-17-2900
UT WoS 000439199100028
Keywords in English leukocyte antigen
Tags 14110811, rivok
Tags International impact, Reviewed
Changed by Changed by: Mgr. Michal Petr, učo 65024. Changed: 23/4/2024 10:14.
Abstract
A growing number of loci within the human leukocyte antigen (HLA) region have been implicated in non-Hodgkin lymphoma (NHL) etiology. Here, we test a complementary hypothesis of "heterozygote advantage" regarding the role of HLA and NHL, whereby HLA diversity is beneficial and homozygous HLA loci are associated with increased disease risk. HLA alleles at class I and II loci were imputed from genome-wide association studies (GWAS) using SNP2HLA for 3,617 diffuse large B-cell lymphomas (DLBCL), 2,686 follicular lymphomas (FL), 2,878 chronic lymphocytic leukemia/small lymphocytic lymphomas (CLL/SLL), 741 marginal zone lymphomas (MZL), and 8,753 controls of European descent. Both DLBCL and MZL risk were elevated with homozygosity at class I HLA-B and -C loci (OR DLBCL = 1.31, 95% CI = 1.06-1.60; OR MZL = 1.45, 95% CI = 1.12-1.89) and class II HLA-DRB1 locus (OR DLBCL = 2.10, 95% CI = 1.24-3.55; OR MZL = 2.10, 95% CI = 0.99-4.45). Increased FL risk was observed with the overall increase in number of homozygous HLA class II loci (P trend < 0.0001, FDR = 0.0005). These results support a role for HLA zygosity in NHL etiology and suggests that distinct immune pathways may underly the etiology of the different NHL subtypes. Significance: HLA gene diversity reduces risk for non-Hodgkin lymphoma. (C) 2018 AACR.
PrintDisplayed: 21/8/2024 23:26